Literature DB >> 8327113

Database for serial magnetic resonance imaging in multiple sclerosis.

F Barkhof1, A J Thompson, L Kappos, J J Nauta, T Yousri, I Berry, G Scotti, B Appel, P S Tofts, D H Miller.   

Abstract

The unique sensitivity of magnetic resonance imaging (MRI) in detecting disease activity in multiple sclerosis (MS) and the objective nature of the information obtained suggest that MRI will be a useful and reliable way of monitoring treatment trials. There is a need to develop an appropriate database which would provide a standardised means of assessment, not only of MRI, but also of essential clinical information. As part of the program of Concerted Action in Multiple Sclerosis, funded by the Commission of the European Community (CEC), we have developed a database for recording serial brain MRI results. The database consists of core, entry and follow-up sections. Both entry and follow-up parts are subdivided into clinical, MR system and MRI data. We expect that the use of this database will maximise efficiency of MRI monitoring in MS treatment trials, particularly in multicentre studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327113     DOI: 10.1007/bf00588371

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  29 in total

1.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

2.  Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.

Authors:  F Barkhof; O R Hommes; P Scheltens; J Valk
Journal:  Neurology       Date:  1991-08       Impact factor: 9.910

3.  Long term follow-up of multiple sclerosis by standardized, non-contrast-enhanced magnetic resonance imaging.

Authors:  L Truyen; J Gheuens; P M Parizel; F L Van de Vyver; J J Martin
Journal:  J Neurol Sci       Date:  1991-11       Impact factor: 3.181

4.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

5.  Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

Authors:  E W Willoughby; E Grochowski; D K Li; J Oger; L F Kastrukoff; D W Paty
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

6.  Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months.

Authors:  R A Koopmans; D K Li; J J Oger; L F Kastrukoff; C Jardine; L Costley; S Hall; E W Grochowski; D W Paty
Journal:  Ann Neurol       Date:  1989-08       Impact factor: 10.422

7.  Multiple sclerosis: a serial study using MRI in relapsing patients.

Authors:  C Isaac; D K Li; M Genton; C Jardine; E Grochowski; M Palmer; L F Kastrukoff; J Oger; D W Paty
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

8.  Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.

Authors:  S Bastianello; C Pozzilli; S Bernardi; L Bozzao; L M Fantozzi; C Buttinelli; C Fieschi
Journal:  Neurology       Date:  1990-04       Impact factor: 9.910

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.